Back to results

The vBlocT2D Study

Primary Purpose

Type2 Diabetes, Obesity

Status

Withdrawn

Phase

Not Applicable

Locations

United States

Study Type

Interventional

Intervention

vBloc Therapy

About this trial

This is an interventional treatment trial for Type2 Diabetes

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Type 2 diabetes with HbA1c level 7-10% inclusive, AND known duration of disease ≤10 years, AND
Male or female (females of child-birth potential not pregnant at implant or for duration of study), AND
Age 18 years or older, AND
Body mass index (BMI) 35-45 kg/m2 inclusive, AND
Attempt and failed diet, exercise and behavioral modification program within past five years,

Exclusion Criteria:

Use of GLP-1 receptor agonists for diabetes currently or within past 6 months
Contraindications to vBloc (permanently implanted, electrical-powered medical device or gastrointestinal device or prosthesis (e.g. pacemakers, implanted defibrillators, neurostimulators))
Patients for whom magnetic resonance imaging (MRI), shortwave, microwave, or therapeutic ultrasound diathermy is planned (Note: Diathermy is any treatment that uses high-frequency electromagnetic radiation, electric currents, or ultrasonic waves to produce heat in body tissues. Patients absolutely CANNOT be treated with any type of shortwave, microwave, or therapeutic ultrasound diathermy device whether or not it is used to produce heat. These treatments should not be applied anywhere on the body)
Underlying disease(s) likely to (a) limit life span to less than study duration and/or (b) increase risk of intervention outside of the study and/or (c) limit ability to participate in outcomes assessment and/or (d) limit participation
Previous bariatric or upper GI surgery
Excessive alcohol intake
Current smokers or smoking cessation in prior 3 months
An underlying disease known to have important effects on glucose metabolism
Active infections
Anemia (Hemoglobin <11g/dl in women, <12 g/dl in men) or known coagulopathy
Chronic kidney disease manifest as serum creatinine >2.0 mg/dl
Diabetic retinopathy requiring photocoagulation therapy
Symptomatic diabetic gastroparesis
Cardiovascular disease, including uncontrolled hypertension and symptomatic congestive heart failure
Cirrhosis of the liver, portal hypertension, or esophageal varices
Symptomatic esophageal reflux
Conditions or behaviors likely to affect the conduct of the vBloc Study
1. Unable or unwilling to give informed consent
2. Unable to adequately communicate with clinic staff
3. Current or anticipated participation in another intervention research project that would interfere with any of the interventions/outcomes in vBloc study
4. Likely to move away from participating clinic in next 2 years
5. Current (or anticipated) pregnancy and lactation.
6. Major psychiatric disorder that, in the opinion of investigators, would impede participation in the study
7. Weight loss >7% in past two months for any reason except postpartum weight loss.
Additional conditions may serve as criteria for exclusion at the discretion of the study investigators.

Sites / Locations

Kaiser Permanente South Bay Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

vBloc Therapy + Usual Care for Type 2 Diabetes

Usual Care for Type 2 Diabetes

Arm Description

Outcomes

Primary Outcome Measures

Mean reduction in HbA1c

Secondary Outcome Measures

Full Information

NCT ID

NCT03355092

First Posted

November 22, 2017

Last Updated

April 25, 2019

Sponsor

Kaiser Permanente

1. Study Identification

Unique Protocol Identification Number

NCT03355092

Brief Title

The vBlocT2D Study

Official Title

vBloc Therapy for Obese Subjects With Type 2 Diabetes- A Randomized Controlled Clinical Trial

Study Type

Interventional

2. Study Status

Record Verification Date

April 2019

Overall Recruitment Status

Withdrawn

Why Stopped

Funding

Study Start Date

February 23, 2018 (Actual)

Primary Completion Date

November 30, 2018 (Actual)

Study Completion Date

November 30, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Kaiser Permanente

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Studies a U.S. FDA-regulated Device Product

Yes

Product Manufactured in and Exported from the U.S.

5. Study Description

Brief Summary

Overall aim: To demonstrate that weight loss through vBloc Therapy in combination with usual care will achieve better glycemic control for patients with obesity and type 2 diabetes than usual care alone. Duration: Participants will be asked to participate in a 12 month study that involves a baseline visit and research follow-up visits at 3, 6, 9, and 12 months. Sample Size: 60 participants will be enrolled in the study. Of these, 30 will be randomized to vBloc therapy and 30 will be randomized to usual care.

Detailed Description

The vBlocT2D study is a two arm, randomized, controlled, unblinded clinical trial in which 60 adult patients with T2D with moderate to extreme obesity (BMI 35-45 kg/m2) and suboptimal glycemic control (glycated haemoglobin (HbA1c) 7-10%) without significant diabetic complications, will be randomized to usual care alone (n=30) or vBloc therapy plus usual care (n=30) to assess the superiority of vBloc therapy plus usual care than standard usual care alone in improving diabetic control. The vBloc therapy will be delivered through an electrical and reversible vagal blocking device (the Maestro Rechargeable System) implanted using laparoscopic surgery. The device was approved by the FDA in 2015 for weight loss in adults with BMI 40-45 kg/m2, or BMI 35-39.9 kg/m2 with one or more obesity-related co-morbid conditions. The study will recruit patients over a 12-month period and follow each individual for 12-months post intervention. The primary outcome is change in HbA1c at 12-months post randomization. The secondary outcomes are changes in weight, waist and hip circumferences, blood pressure, lipids, insulin sensitivity and β-cell health measured through oral glucose tolerance testing, dietary intake, eating behaviors, physical activity, quality of life and potential circulating biomarkers. Medication use, clinical labs and adverse events will be compared as well.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Type2 Diabetes, Obesity

7. Study Design

Primary Purpose

Treatment

Study Phase

Not Applicable

Interventional Study Model

Parallel Assignment

Masking

None (Open Label)

Allocation

Randomized

Enrollment

0 (Actual)

8. Arms, Groups, and Interventions

Arm Title

vBloc Therapy + Usual Care for Type 2 Diabetes

Arm Type

Experimental

Arm Title

Usual Care for Type 2 Diabetes

Arm Type

No Intervention

Intervention Type

Device

Intervention Name(s)

vBloc Therapy

Intervention Description

The vBloc device will be placed using a laparoscopic procedure. The participants will be followed according to standard clinical practice and vBloc therapy protocol under the supervision of study surgeons. . Pre-operative testing will be conducted per surgeon's evaluation. Participants will receive weight management education according to the vBloc Therapy protocol.

Primary Outcome Measure Information:

Title

Mean reduction in HbA1c

Time Frame

at 12 months after baseline

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Type 2 diabetes with HbA1c level 7-10% inclusive, AND known duration of disease ≤10 years, AND Male or female (females of child-birth potential not pregnant at implant or for duration of study), AND Age 18 years or older, AND Body mass index (BMI) 35-45 kg/m2 inclusive, AND Attempt and failed diet, exercise and behavioral modification program within past five years, Exclusion Criteria: Use of GLP-1 receptor agonists for diabetes currently or within past 6 months Contraindications to vBloc (permanently implanted, electrical-powered medical device or gastrointestinal device or prosthesis (e.g. pacemakers, implanted defibrillators, neurostimulators)) Patients for whom magnetic resonance imaging (MRI), shortwave, microwave, or therapeutic ultrasound diathermy is planned (Note: Diathermy is any treatment that uses high-frequency electromagnetic radiation, electric currents, or ultrasonic waves to produce heat in body tissues. Patients absolutely CANNOT be treated with any type of shortwave, microwave, or therapeutic ultrasound diathermy device whether or not it is used to produce heat. These treatments should not be applied anywhere on the body) Underlying disease(s) likely to (a) limit life span to less than study duration and/or (b) increase risk of intervention outside of the study and/or (c) limit ability to participate in outcomes assessment and/or (d) limit participation Previous bariatric or upper GI surgery Excessive alcohol intake Current smokers or smoking cessation in prior 3 months An underlying disease known to have important effects on glucose metabolism Active infections Anemia (Hemoglobin <11g/dl in women, <12 g/dl in men) or known coagulopathy Chronic kidney disease manifest as serum creatinine >2.0 mg/dl Diabetic retinopathy requiring photocoagulation therapy Symptomatic diabetic gastroparesis Cardiovascular disease, including uncontrolled hypertension and symptomatic congestive heart failure Cirrhosis of the liver, portal hypertension, or esophageal varices Symptomatic esophageal reflux Conditions or behaviors likely to affect the conduct of the vBloc Study Unable or unwilling to give informed consent Unable to adequately communicate with clinic staff Current or anticipated participation in another intervention research project that would interfere with any of the interventions/outcomes in vBloc study Likely to move away from participating clinic in next 2 years Current (or anticipated) pregnancy and lactation. Major psychiatric disorder that, in the opinion of investigators, would impede participation in the study Weight loss >7% in past two months for any reason except postpartum weight loss. Additional conditions may serve as criteria for exclusion at the discretion of the study investigators.

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Anny Xiang, PhD

Organizational Affiliation

Kaiser Permanente

Official's Role

Principal Investigator

Facility Information:

Facility Name

Kaiser Permanente South Bay Medical Center

City

Harbor City

State/Province

California

ZIP/Postal Code

90710

Country

United States

12. IPD Sharing Statement

Learn more about this trial

The vBlocT2D Study

We'll reach out to this number within 24 hrs